Birchview Capital
Latest statistics and disclosures from Birchview Capital's latest quarterly 13F-HR filing:
- Top 5 stock holdings are BMY, BDSX, NBIX, PRTA, AZYO, and represent 62.25% of Birchview Capital's stock portfolio.
- Added to shares of these 8 stocks: BDSX (+$6.1M), ATEC, HALO, PRTA, AZYO, TXG, KROS, KPTI.
- Started 3 new stock positions in TXG, KROS, HALO.
- Reduced shares in these 10 stocks: Continental Resources, , VTYX, NARI, AVEO, IRTC, GOSS, FOLD, NBIX, Biohaven Pharmaceutical Holding.
- Sold out of its positions in Chemocentryx, Continental Resources, Contrafect, IRTC, NARI, LSF.
- Birchview Capital was a net buyer of stock by $2.6M.
- Birchview Capital has $142M in assets under management (AUM), dropping by -0.31%.
- Central Index Key (CIK): 0001618205
Tip: Access up to 7 years of quarterly data
Positions held by Birchview Capital consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Birchview Capital
Birchview Capital holds 57 positions in its portfolio as reported in the December 2022 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Bristol Myers Squibb (BMY) | 37.0 | $52M | 728k | 71.95 | ||
| Biodesix (BDSX) | 8.2 | $12M | +112% | 5.0M | 2.30 | |
| Neurocrine Biosciences (NBIX) | 7.1 | $10M | 84k | 119.44 | ||
| Prothena Corp SHS (PRTA) | 5.4 | $7.7M | +6% | 127k | 60.25 | |
| Aziyo Biologics (AZYO) | 4.5 | $6.4M | +6% | 1.5M | 4.25 | |
| Quidel Corporation | 3.7 | $5.3M | 61k | 85.67 | ||
| Encana Corporation (OVV) | 3.0 | $4.3M | 84k | 50.71 | ||
| United Therapeutics Corporation (UTHR) | 2.9 | $4.2M | 15k | 278.07 | ||
| ACADIA Pharmaceuticals (ACAD) | 2.8 | $4.0M | 249k | 15.92 | ||
| Phreesia (PHR) | 1.9 | $2.7M | 83k | 32.36 | ||
| Harrow Health (HROW) | 1.9 | $2.7M | 180k | 14.76 | ||
| Albireo Pharma (ALBO) | 1.8 | $2.5M | 117k | 21.61 | ||
| Masimo Corporation (MASI) | 1.6 | $2.3M | 15k | 147.97 | ||
| Inhibrx (INBX) | 1.2 | $1.7M | 70k | 24.64 | ||
Setup an alertBirchview Capital will file the next quarterly 13-HR in about 2 months. Would you like to be notified? |
||||||
| Foghorn Therapeutics (FHTX) | 1.2 | $1.7M | 265k | 6.38 | ||
| Accelr8 Technology (AXDX) | 1.1 | $1.6M | 2.3M | 0.71 | ||
| Aveo Pharmaceuticals (AVEO) | 1.1 | $1.5M | -28% | 100k | 14.95 | |
| Alkermes SHS (ALKS) | 0.9 | $1.3M | 50k | 26.14 | ||
| Cytokinetics (CYTK) | 0.8 | $1.1M | 25k | 45.84 | ||
| Alphatec Holdings (ATEC) | 0.8 | $1.1M | +800% | 90k | 12.36 | |
| Corcept Therapeutics Incorporated (CORT) | 0.7 | $1.0M | 50k | 20.32 | ||
| Karyopharm Therapeutics (KPTI) | 0.7 | $991k | +8% | 291k | 3.40 | |
| Equitrans Midstream Corp (ETRN) | 0.6 | $891k | 133k | 6.70 | ||
| Pioneer Natural Resources (PXD) | 0.6 | $868k | 3.8k | 228.42 | ||
| Docgo (DCGO) | 0.5 | $778k | 110k | 7.07 | ||
| ImmunoGen (IMGN) | 0.5 | $744k | 150k | 4.96 | ||
| Ventyx Biosciences (VTYX) | 0.5 | $721k | -51% | 22k | 32.77 | |
| Bluebird Bio (BLUE) | 0.5 | $678k | 98k | 6.92 | ||
| Apellis Pharmaceuticals (APLS) | 0.4 | $621k | 12k | 51.75 | ||
| Halozyme Therapeutics (HALO) | 0.4 | $569k | NEW | 10k | 56.90 | |
| 2seventy Bio (TSVT) | 0.4 | $561k | 60k | 9.38 | ||
| Iveric Bio (ISEE) | 0.4 | $535k | 25k | 21.40 | ||
| Silk Road Medical Inc Common (SILK) | 0.4 | $529k | 10k | 52.90 | ||
| Arvinas Ord (ARVN) | 0.4 | $513k | 15k | 34.20 | ||
| Soleno Therapeutics | 0.3 | $485k | 245k | 1.98 | ||
| Kiniksa Pharmaceuticals (KNSA) | 0.3 | $449k | 30k | 14.97 | ||
| Protagonist Therapeutics (PTGX) | 0.3 | $415k | 38k | 10.92 | ||
| Xenon Pharmaceuticals (XENE) | 0.3 | $394k | 10k | 39.40 | ||
| 10x Genomics Cl A Com (TXG) | 0.3 | $364k | NEW | 10k | 36.40 | |
| Amicus Therapeutics (FOLD) | 0.2 | $342k | -26% | 28k | 12.21 | |
| Keros Therapeutics (KROS) | 0.2 | $336k | NEW | 7.0k | 48.00 | |
| Sarepta Therapeutics (SRPT) | 0.2 | $324k | 2.5k | 129.60 | ||
| Xencor (XNCR) | 0.2 | $320k | 12k | 26.02 | ||
| Kalvista Pharmaceuticals (KALV) | 0.2 | $270k | 40k | 6.75 | ||
| Nektar Therapeutics (NKTR) | 0.2 | $267k | -7% | 118k | 2.26 | |
| Cullinan Oncology (CGEM) | 0.2 | $265k | 25k | 10.55 | ||
| BioCryst Pharmaceuticals (BCRX) | 0.2 | $230k | 20k | 11.50 | ||
| G1 Therapeutics (GTHX) | 0.2 | $217k | 40k | 5.42 | ||
| Inflarx Nv (IFRX) | 0.2 | $217k | 70k | 3.10 | ||
| Gossamer Bio (GOSS) | 0.2 | $215k | -37% | 99k | 2.17 | |
| Stoke Therapeutics (STOK) | 0.1 | $138k | 15k | 9.20 | ||
| Concert Pharmaceuticals I equity (CNCE) | 0.1 | $117k | 20k | 5.85 | ||
| Biohaven Pharmaceutical Holding | 0.1 | $102k | -50% | 7.4k | 13.85 | |
| Angion Biomedica Corp (ANGN) | 0.0 | $44k | 54k | 0.81 | ||
| Yield10 Bioscience | 0.0 | $31k | 19k | 1.65 | ||
| Aspira Womens Health (AWH) | 0.0 | $20k | 60k | 0.33 | ||
| Sientra (SIEN) | 0.0 | $8.0k | 40k | 0.20 | ||
Past Filings by Birchview Capital
SEC 13F filings are viewable for Birchview Capital going back to 2014
- Birchview Capital 2022 Q4 filed Feb. 3, 2023
- Birchview Capital 2022 Q3 restated filed Nov. 28, 2022
- Birchview Capital 2022 Q3 filed Nov. 7, 2022
- Birchview Capital 2022 Q2 filed Aug. 12, 2022
- Birchview Capital 2022 Q1 filed May 13, 2022
- Birchview Capital 2021 Q4 filed Feb. 14, 2022
- Birchview Capital 2021 Q3 filed Nov. 12, 2021
- Birchview Capital 2021 Q2 filed Aug. 10, 2021
- Birchview Capital 2021 Q1 filed May 14, 2021
- Birchview Capital 2020 Q4 filed Feb. 9, 2021
- Birchview Capital 2020 Q3 restated filed Nov. 12, 2020
- Birchview Capital 2020 Q3 filed Nov. 12, 2020
- Birchview Capital 2020 Q2 restated filed Sept. 25, 2020
- Birchview Capital 2020 Q2 filed Aug. 10, 2020
- Birchview Capital 2020 Q1 filed May 12, 2020
- Birchview Capital 2019 Q4 filed Feb. 12, 2020